Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02572245 · ClinicalTrials.gov registry record · Phase 1
A Study of PF-06410293 Following Subcutaneous Administration Using A Prefilled Syringe Or A Prefilled Pen In Healthy Adult Subjects
A Phase 1 study of Healthy Subjects, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 164
- Enrollment target
- 1
- Study location
NCT02572245 is a Phase 1 study of Healthy Subjects that has completed, run by Pfizer. The registered enrollment target is 164 participants, above the 126-participant average among 69 other Healthy Subjects trials with a reported enrollment target (30% higher). The trial reports 1 study location across 1 state.
The verdict
NCT02572245, a Phase 1 study of Healthy Subjects, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 164 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a study comparing adalimumab Pfizer (PF-06410293) administered as a subcutaneous(SC) injection using a pre-filled syringe (PFS) or pre-filled pen in healthy adult subjects
Conditions Studied
Interventions
- DEVICE PF-06410293 PFS
- DEVICE PF-06410293 PFP
Study Locations (1)
Texas
- ICON Early Phase Services, LLC - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 164 participants |
| Start Date | 2016-01 |
| Est. Completion | 2016-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02572245
The ClinicalTrials.gov registry entry for NCT02572245 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 164 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 126-participant average among 69 other Healthy Subjects trials with a reported enrollment target (30% higher). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Healthy Subjects appearing as the primary indexed condition, and to 2 interventions - of which PF-06410293 PFS is the first listed.
NCT02572245 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT02572245 about?
NCT02572245 is a clinical study titled "A Study of PF-06410293 Following Subcutaneous Administration Using A Prefilled Syringe Or A Prefilled Pen In Healthy Adult Subjects". This is a study comparing adalimumab Pfizer (PF-06410293) administered as a subcutaneous(SC) injection using a pre-filled syringe (PFS) or pre-filled pen in healthy adult subjects
What is the current status of trial NCT02572245?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 164 participants. The study started on 2016-01. Estimated completion is 2016-05.
What conditions does trial NCT02572245 study?
This clinical trial studies the following conditions: Healthy Subjects.
What interventions are being tested in trial NCT02572245?
The interventions under investigation include: PF-06410293 PFS (DEVICE), PF-06410293 PFP (DEVICE).
Who is sponsoring clinical trial NCT02572245?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02572245 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Subjects
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase I Study of ICP-332 in Healthy Subjects
RECRUITING · Phase 1
-
A Study to Investigate HLA-G Targeted Exosome (SOB100) in Healthy Subjects
RECRUITING · Phase 1
-
Phase 1 Study of Intravaginal KB15A
RECRUITING · Phase 1
-
A Study to Compare to the Pharmacokinetic Profile of Two Paracetamol Formulations
COMPLETED · Phase 1
-
Pharmacokinetic Study Investigating the Extent of Paracetamol Absorption From a New Formulation of Paracetamol Compared With Panadol®
COMPLETED · Phase 1
-
A Drug-Drug Interaction Study to Evaluate the Effect of Rifampin on the Pharmacokinetics of Apremilast
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.